Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03735446 |
Title | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial |
Recruitment | Terminated |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Dana-Farber Cancer Institute |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details |